DOXAZOSINE SUBSTIPHARM LP 8 mg, extended-release tablet 28 tablets
Active ingredients: Doxazosin, Doxazosin mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DOXAZOSINE SUBSTIPHARM LP 8 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC PVDC aluminium de 28 comprimé(s) en conditionnement calendaire
- Marketing authorisation holder
- SUBSTIPHARM
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 24 Jul 2013
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66978789CIP72165679CIP133400921656794Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉSILATE DE DOXAZOSINEcomprimé | — | SA |
| DOXAZOSINEcomprimé | 8 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.